Protalix BioTherapeutics (PLX) Cost of Revenue (2010 - 2026)

Protalix BioTherapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 49.55% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $22.9 million (down 23.27% YoY), while the FY2025 annual figure was $27.0 million, up 11.0% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.1 million, down from $4.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $9.5 million in Q2 2024, with the low at $2.4 million in Q4 2022.
• The 5-year median for Cost of Revenue is $5.9 million (2025), against an average of $5.8 million.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 269.46% in 2023, then tumbled 56.12% in 2024.
• Protalix BioTherapeutics' Cost of Revenue stood at $2.4 million in 2022, then jumped by 269.46% to $8.9 million in 2023, then sank by 56.12% to $3.9 million in 2024, then advanced by 18.86% to $4.6 million in 2025, then dropped by 10.65% to $4.1 million in 2026.
• Business Quant data shows PLX's Cost of Revenue at $4.1 million in Q1 2026, $4.6 million in Q4 2025, and $8.3 million in Q3 2025.